← Leaderboards
Kenneth L Urish
University Of Pittsburgh At Pittsburgh
$2,016,497
Attributed
$3,044,559
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $807.5K · FY2017–25$1M$750K$500K$250K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,044,559 · 4
By mechanism
R01$1,608,341 · 1
K08$830,894 · 1
R21$447,783 · 1
R03$157,541 · 1
Top collaborators
- James B. Doub5 shared
Most similar at University Of Pittsburgh At Pittsburgh
Same institution · by research overlap
- James B. Doub$1,218,837
- Ghady Haidar$895,725
- Shihui Liu$7,676,261
- Graham F. Hatfull$17,993,179
- Jihong Li$859,097
Others in their field
Other Emerging Leaders on “Implant”
- Bryan L McLaughlin · Micro-Leads, Inc.$14,225,420
- Nanthia A Suthana · University Of California Los Angeles$12,792,001
- Shadi Dayeh · University Of California, San Diego$11,494,972
- Magdalena Zernicka-Goetz · California Institute Of Technology$11,182,591
- Leah Johnson · Research Triangle Institute$10,876,154
- James H. Segars · Child Health And Human Development$9,029,806
Research focus
ImplantKnee Replacement ArthroplastyOperative Surgical ProceduresBacteriaMicrobial BiofilmsNovel TherapeuticsMortalityStaphylococcus AureusAntibioticsComplicationFailurePhenotypeIn VitroSurfaceIn VivoFutureFundingClinical ResearchSuccessTreatment StrategyInfectionImproved OutcomeAnimal ModelNovel Therapeutic Intervention
Grant awards (13)
Preclinical Research to Determine Prosthetic Joint Infection Pathophysiology Needed to Direct Clinical Bacteriophage Therapy$447,783
R21 · FY2025 · AI · contact PI
The Role of Teichoic Acid Glycosylation in Phage Activity and Selection in an Ongoing FDA Phase II/III Clinical Study of Bacteriophage Therapy in Chronic Periprosthetic Joint Infection$359,683
R01 · FY2025 · AR · contact PI
The Role of Teichoic Acid Glycosylation in Phage Activity and Selection in an Ongoing FDA Phase II/III Clinical Study of Bacteriophage Therapy in Chronic Periprosthetic Joint Infection$396,697
R01 · FY2024 · AR · contact PI
The Role of Teichoic Acid Glycosylation in Phage Activity and Selection in an Ongoing FDA Phase II/III Clinical Study of Bacteriophage Therapy in Chronic Periprosthetic Joint Infection$415,459
R01 · FY2023 · AR · contact PI
The Role of Teichoic Acid Glycosylation in Phage Activity and Selection in an Ongoing FDA Phase II/III Clinical Study of Bacteriophage Therapy in Chronic Periprosthetic Joint Infection$436,502
R01 · FY2022 · AR · contact PI
The Role of Biofilm Formation in Antibiotic Tolerant Periprosthetic Joint Infection$79,291
R03 · FY2022 · AR · contact PI
Biofilm antibiotic tolerance in periprosthetic joint infection$166,016
K08 · FY2021 · AR · contact PI
The Role of Biofilm Formation in Antibiotic Tolerant Periprosthetic Joint Infection$78,250
R03 · FY2021 · AR · contact PI
Biofilm antibiotic tolerance in periprosthetic joint infection$166,016
K08 · FY2020 · AR · contact PI
Biofilm antibiotic tolerance in periprosthetic joint infection$814
K08 · FY2020 · AR · contact PI
Biofilm antibiotic tolerance in periprosthetic joint infection$166,016
K08 · FY2019 · AR · contact PI
Biofilm antibiotic tolerance in periprosthetic joint infection$166,016
K08 · FY2018 · AR · contact PI
Biofilm antibiotic tolerance in periprosthetic joint infection$166,016
K08 · FY2017 · AR · contact PI